The Peptide Drug Problem
Peptide drugs are among the most powerful medicines ever developed. Peptides can hit targets that small molecules cannot reach, and they are more specific than many antibody drugs. But they have one fatal flaw: they are eaten alive in the gut.
The digestive system is an extraordinarily effective protein destruction machine. When you eat a piece of steak, enzymes reduce those proteins to individual amino acids within hours. The same fate awaits any peptide drug taken by mouth. This is why insulin, GLP-1 analogues like semaglutide, and virtually all other peptide drugs must be injected — oral delivery gives them a bioavailability of less than 1%.
How Digestive Enzymes Destroy Linear Peptides
The gut deploys enzymes in two stages:
In the stomach: Pepsin, activated at pH ~2, begins cleaving peptide bonds between specific amino acids. Heat and acid also begin unfolding the protein's 3D structure, exposing previously hidden cleavage sites.
In the small intestine: A battery of pancreatic enzymes — trypsin, chymotrypsin, elastase — continue the degradation. Aminopeptidases and carboxypeptidases attack from the free N- and C-termini, progressively stripping amino acids from both ends. By the time most linear peptide drugs reach the intestinal wall for absorption, they have been reduced to fragments too small to be therapeutically useful.
Why Cyclopeptides Resist Every Stage of Digestion
No free termini: The head-to-tail cyclic backbone eliminates the N- and C-terminal ends that exoproteases (aminopeptidase and carboxypeptidase) attack. Without ends, this entire class of digestive enzymes is ineffective.
The Cyclic Cystine Knot blocks endoproteases: Even without free ends, endoproteases (trypsin, chymotrypsin, pepsin) could theoretically attack internal peptide bonds. The CCK prevents this by maintaining such a compact, rigid 3D structure that enzyme active sites cannot access the backbone. The molecule would need to be physically unfolded for cleavage to occur — and the CCK makes unfolding thermodynamically impossible without breaking covalent bonds.
Acid and heat resistance: Stomach acid (pH 2) denatures most proteins by disrupting the hydrogen bonds and hydrophobic interactions that maintain their shape. In cyclotides, the shape is maintained by covalent disulfide bonds and the topological knot — acid cannot disrupt these. Kalata B1, the first cyclotide, famously survives boiling — a property Gran observed in 1960s Congo.
Membrane permeability: Beyond survival, cyclotides also interact favourably with cell membranes. Their amphipathic surface (partly hydrophilic, partly hydrophobic) allows them to partition into and cross lipid bilayers — a necessary step for intestinal absorption. Studies have shown that cyclotides can permeate gut epithelial cells, reaching the bloodstream intact.
"Kalata B1 was first brewed in a boiling tea in 1960s Congo — its oral activity observed by local midwives centuries before modern pharmacology could explain it."
Demonstrated Oral Bioavailability
The oral bioavailability of cyclotides has been studied in animal models and in human clinical trials:
- Kalata B1 has demonstrated measurable oral bioavailability in rodent studies at levels comparable to several peptide drugs currently in clinical use.
- [T20K]kalata B1, engineered by Prof. Christian Gruber's group at MedUni Vienna, is the first cyclotide in human clinical trials — and is administered orally for multiple sclerosis.
- Dithioether macrocyclic peptides (related class) achieved 18% oral bioavailability in rat studies.
- Research in Nature Chemical Biology (2023) demonstrated oral bioavailability in de novo designed cyclic peptides targeting the same design principles.
Drug Grafting: Borrowing Cyclotide Armour for New Medicines
The most commercially significant application of cyclotide stability is drug grafting. The concept, pioneered by Professor David Craik's group at UQ, is elegant: take a therapeutically active peptide sequence — one that would be destroyed in the gut if taken orally — and splice it into a loop of the cyclotide scaffold. The cyclotide holds the active sequence in its correct 3D conformation, protects it from digestion, and carries it intact to the target.
In grafting, the cyclotide acts as a scaffold. The six loops of the CCK structure are surface-exposed and tolerant of amino acid substitutions — they can accommodate guest sequences of several amino acids while the CCK core maintains its stability. This creates a "plug and play" drug design platform for any peptide sequence that needs to be delivered orally.
Active research projects using this approach:
- Pain relief — conotoxin (cone snail venom) peptide sequences grafted into cyclotide scaffolds; results 100× more potent than gabapentin in animal studies (Craik lab, UQ)
- Multiple sclerosis — T20K in clinical trials (Gruber lab, MedUni Vienna)
- Cancer — CXCR4-antagonist and p53-activating sequences (Camarero lab, USC)
- Obesity — satiety signalling peptides in plant-grown cyclotide format (Craik lab / Phyllome)
The Broader Significance
The oral bioavailability of cyclopeptides represents one of the most significant developments in pharmaceutical drug delivery in decades. It potentially offers:
- Elimination of injections for biological drugs that currently require them
- Lower manufacturing costs through plant-based production (versus injectable biologics requiring sterile manufacturing)
- Improved patient compliance — oral dosing vs. self-injection
- New drug targets — peptide drugs can hit intracellular and extracellular targets that small molecules cannot, and antibodies cannot cross cell membranes
The cyclopeptide oral delivery platform is not a theoretical future — it is in clinical trials now, in 2025.
Four Mechanisms of Digestive Resistance
No Free Termini
The head-to-tail cyclic backbone has no N- or C-terminus for exoproteases to grip. Aminopeptidase and carboxypeptidase — two major gut enzymes — are rendered completely ineffective.
Cystine Knot Rigidity
Three interlocking disulfide bonds form the Cyclic Cystine Knot, creating a core so compact and rigid that endoprotease active sites cannot physically access internal peptide bonds.
Acid & Heat Stability
Stomach acid (pH 2) and temperatures up to 100°C leave cyclotides intact. Their shape is locked by covalent bonds, not the fragile hydrogen bonds that acid unravels in ordinary proteins.
Membrane Permeability
The amphipathic surface of cyclotides allows them to partition into and cross lipid bilayers. After surviving digestion, they can permeate gut epithelial cells and enter the bloodstream intact.